NCT02940912View on ClinicalTrials.gov

Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2021

Study Completion Date

April 12, 2021

Conditions
Parkinson Disease
Interventions
DRUG

Apomorphine

cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.

DRUG

Placebo

cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.

Trial Locations (9)

13385

Hôpital de la TIMONE, Marseille

30029

CHU de NIMES, Nîmes

34070

Clinique Beau Soleil, Montpellier

35033

Chu Ponchaillou, Rennes

44093

CHU de NANTES - HOPITAL NORD, Nantes

63001

Chu Gabriel Montpied, Clermont-Ferrand

67091

Hôpital CIVIL, Strasbourg

67200

Hôpital de HAUTEPIERRE, Strasbourg

03200

Centre hospitalier JACQUES LACARIN, Vichy

All Listed Sponsors
lead

Clinique Beau Soleil

OTHER

NCT02940912 - Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter